318 related articles for article (PubMed ID: 25971881)
21. Prokinetics and fundic relaxants in upper functional GI disorders.
Tack J
Curr Opin Pharmacol; 2008 Dec; 8(6):690-6. PubMed ID: 18940266
[TBL] [Abstract][Full Text] [Related]
22. Domperidone: a peripherally acting dopamine2-receptor antagonist.
Barone JA
Ann Pharmacother; 1999 Apr; 33(4):429-40. PubMed ID: 10332535
[TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal motility disorders: an update.
Lacy BE; Weiser K
Dig Dis; 2006; 24(3-4):228-42. PubMed ID: 16849850
[TBL] [Abstract][Full Text] [Related]
24. Making a case for domperidone in the treatment of gastrointestinal motility disorders.
Ahmad N; Keith-Ferris J; Gooden E; Abell T
Curr Opin Pharmacol; 2006 Dec; 6(6):571-6. PubMed ID: 16997628
[TBL] [Abstract][Full Text] [Related]
25. Investigational drugs for the treatment of spinal cord injury: review of preclinical studies and evaluation of clinical trials from Phase I to II.
Nagoshi N; Fehlings MG
Expert Opin Investig Drugs; 2015 May; 24(5):645-58. PubMed ID: 25645889
[TBL] [Abstract][Full Text] [Related]
26. Peripheral opioids for functional GI disease: a reappraisal.
Lembo A
Dig Dis; 2006; 24(1-2):91-8. PubMed ID: 16699267
[TBL] [Abstract][Full Text] [Related]
27. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
Jovanović-Mićić D; Samardzić R; Beleslin B
Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
[TBL] [Abstract][Full Text] [Related]
28. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
Lockwood JT; Remington G
Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
[TBL] [Abstract][Full Text] [Related]
29. Prokinetic agents for lower gastrointestinal motility disorders.
Longo WE; Vernava AM
Dis Colon Rectum; 1993 Jul; 36(7):696-708. PubMed ID: 8348856
[TBL] [Abstract][Full Text] [Related]
30. [The potentials of erythromycin derivatives in the treatment of gastrointestinal motility disorders].
Peeters TL
Z Gesamte Inn Med; 1991 Aug; 46(10-11):349-54. PubMed ID: 1926941
[TBL] [Abstract][Full Text] [Related]
31. Ghrelin as a target for gastrointestinal motility disorders.
Greenwood-Van Meerveld B; Kriegsman M; Nelson R
Peptides; 2011 Nov; 32(11):2352-6. PubMed ID: 21453735
[TBL] [Abstract][Full Text] [Related]
32. Prokinetic agents.
Reynolds JC; Putnam PE
Gastroenterol Clin North Am; 1992 Sep; 21(3):567-96. PubMed ID: 1516959
[TBL] [Abstract][Full Text] [Related]
33. Safety of treatment for gastroparesis.
Sarosiek I; Bashashati M; McCallum RW
Expert Opin Drug Saf; 2016 Jul; 15(7):937-45. PubMed ID: 27031006
[TBL] [Abstract][Full Text] [Related]
34. Opioid-induced gastrointestinal dysfunction.
Mehendale SR; Yuan CS
Dig Dis; 2006; 24(1-2):105-12. PubMed ID: 16699269
[TBL] [Abstract][Full Text] [Related]
35. Cisapride: what can we learn from the rise and fall of a prokinetic?
Quigley EM
J Dig Dis; 2011 Jun; 12(3):147-56. PubMed ID: 21615867
[TBL] [Abstract][Full Text] [Related]
36. The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
Gershon MD; Tack J
Gastroenterology; 2007 Jan; 132(1):397-414. PubMed ID: 17241888
[TBL] [Abstract][Full Text] [Related]
37. Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.
Jackson VM; Price DA; Carpino PA
Expert Opin Investig Drugs; 2014 Aug; 23(8):1055-66. PubMed ID: 25000213
[TBL] [Abstract][Full Text] [Related]
38. Effects of Prokinetics on the Digestive Tract.
Usai-Satta P; Lai M; Oppia F; Cabras F
Curr Rev Clin Exp Pharmacol; 2022; 17(3):161-165. PubMed ID: 34455950
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic approaches towards the treatment of gastroinstestinal disorders.
Collingwood S; Witherington J
Drug News Perspect; 2007 Mar; 20(2):139-44. PubMed ID: 17440638
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the pharmacology of gastrointestinal prokinetics.
Tonini M
Pharmacol Res; 1996; 33(4-5):217-26. PubMed ID: 8938012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
